On Monday September 10, I snuck a buy recommendation for shares of Sangamo Therapeutics (SGMO) in just before the 5 p.m. deadline for my daily e-mail update. Here's a full post on the logic for that recommendation. I'd has been a wild ride for shares of biotech Sangamo Therapeutics over the last six weeks or […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
